Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-385-1742
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.76 million
Profitability
Miscellaneous
Employees23
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions
What is Aridis Pharmaceuticals' stock symbol?
Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."
How were Aridis Pharmaceuticals' earnings last quarter?
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) issued its earnings results on Monday, August, 12th. The company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.19. Aridis Pharmaceuticals had a negative net margin of 660.52% and a negative return on equity of 130.22%. View Aridis Pharmaceuticals' Earnings History.
When is Aridis Pharmaceuticals' next earnings date?
What price target have analysts set for ARDS?
5 analysts have issued 1-year price targets for Aridis Pharmaceuticals' stock. Their forecasts range from $23.00 to $40.00. On average, they expect Aridis Pharmaceuticals' stock price to reach $30.60 in the next year. This suggests a possible upside of 241.5% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.
What is the consensus analysts' recommendation for Aridis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.
What are Wall Street analysts saying about Aridis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aridis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. " (8/23/2019)
- 2. Maxim Group analysts commented, "Aridis reported 2Q19 with a net loss of ($8.4M) and ended the period with $8.5M in cash on the balance sheet. This excludes the recently announced partnership with India (private) which brought a $10M equity investment into Aridis, a $5M upfront payment and an option for an additional $10M. As such, Aridis is funded into 2020 and through the next key catalyst, the AR-105 global phase 2 data in ventilator-associated pneumonia (VAP) caused by pseudomonas aeruginosa. The trial, if positive could potentially serve as one of two pivotal studies in support of a BLA." (8/15/2019)
- 3. Northland Securities analysts commented, "We note that the SIBV agreement included purchase of $10MM of Aridis common shares at a 31% premium; a $5MM refundable upfront payment; and an additional $10MM payment upon execution of the agreement by August 31, 2019. The Co.’s key clinical programs continue to progress well. Aridis remains on schedule to report topline data in 3Q19 for AR-105’s Phase 2 clinical trial for the treatment of ventilator- associated pneumonia (VAP) caused by Pseudomonas aeruginosa. 3 program for the treatment of VAP related to Staphylococcus aureus continues to advance, with interim data expected in 1Q20, with full topline data in late-2020." (8/13/2019)
Has Aridis Pharmaceuticals been receiving favorable news coverage?
Press coverage about ARDS stock has been trending positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Aridis Pharmaceuticals.
Are investors shorting Aridis Pharmaceuticals?
Aridis Pharmaceuticals saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 10,600 shares, a drop of 19.7% from the June 30th total of 13,200 shares. Based on an average trading volume of 3,700 shares, the short-interest ratio is currently 2.9 days. Approximately 0.2% of the shares of the stock are sold short. View Aridis Pharmaceuticals' Current Options Chain.
Who are some of Aridis Pharmaceuticals' key competitors?
Some companies that are related to Aridis Pharmaceuticals include Minerva Neurosciences (NERV), Recro Pharma (REPH), Zynerba Pharmaceuticals (ZYNE), Lannett (LCI), Syndax Pharmaceuticals (SNDX), Cyclerion Therapeutics (CYCN), OptiNose (OPTN), Geron (GERN), DURECT (DRRX), CannTrust (CTST), Seres Therapeutics (MCRB), TapImmune (MRKR), NuCana (NCNA), Concert Pharmaceuticals (CNCE) and Flex Pharma (FLKS).
What other stocks do shareholders of Aridis Pharmaceuticals own?
Who are Aridis Pharmaceuticals' key executives?
Aridis Pharmaceuticals' management team includes the folowing people:
- Dr. Eric J. Patzer, Exec. Chairman (Age 70)
- Dr. Vu L. Truong, Founder, CEO, Chief Scientific Officer & Director (Age 55)
- Dr. Alan H. Cohen, Sr. VP of Clinical & Medical Affairs (Age 58)
- Mr. Fred Kurland, Chief Financial Officer (Age 68)
- Mr. Jeffrey J. Fessler J.D., Acting Gen. Counsel (Age 56)
When did Aridis Pharmaceuticals IPO?
(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.
Who are Aridis Pharmaceuticals' major shareholders?
Aridis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.53%).
Which institutional investors are selling Aridis Pharmaceuticals stock?
ARDS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
How do I buy shares of Aridis Pharmaceuticals?
Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aridis Pharmaceuticals' stock price today?
One share of ARDS stock can currently be purchased for approximately $8.96.
How big of a company is Aridis Pharmaceuticals?
Aridis Pharmaceuticals has a market capitalization of $79.83 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.
What is Aridis Pharmaceuticals' official website?
How can I contact Aridis Pharmaceuticals?
Aridis Pharmaceuticals' mailing address is 5941 OPTICAL COURT, SAN JOSE CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]
MarketBeat Community Rating for Aridis Pharmaceuticals (NASDAQ ARDS)
MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
